Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapy
Immunotherapies, including immune checkpoint inhibitors and chimeric antigen receptor-T cell therapies, depend heavily on a healthy and diverse gut microbiome for optimal efficacy. Dysbiosis, or an imbalance in gut microbial composition and function, can diminish immunotherapy responses by altering...
Saved in:
| Main Authors: | Laurence Zitvogel, Andrew A. Almonte |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-04-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/4/e011540.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer
by: Kangkang Ji, et al.
Published: (2025-05-01) -
Next-generation immunotherapy: igniting new hope for lung cancer
by: Molly S. C. Li, et al.
Published: (2024-12-01) -
Harmonizing the Gut Microbiome and Cellular Immunotherapies: The Next Leap in Cancer Treatment
by: Kendall Harrington, et al.
Published: (2025-05-01) -
Transgenic Innovation: Harnessing Cyclotides as Next Generation Pesticides
by: Sathira Deegala, et al.
Published: (2025-02-01) -
Harnessing plant biosynthesis for the development of next-generation therapeutics.
by: Philip Spence, et al.
Published: (2024-11-01)